Global Female Urinary Incontinence Treatment Device Market - 2022-2029

Global Female Urinary Incontinence Treatment Device Market - 2022-2029

Market Overview

Female Urinary Incontinence Treatment Device Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Female urinary incontinence has been diagnosed as a condition that causes involuntary urination. Urinary incontinence or stress urinary incontinence typically occurs during physical activities, such as sneezing, coughing, running, or even during weightlifting, as these activities exert pressure on the urinary bladder. Urinary urge and stress incontinence are different, as the former occurs when the bladder muscles are contracted. Urinary stress incontinence affects women more than men and is mostly due to weak muscle sphincter, which can lead to social isolation. Female urinary incontinence is of two types: the first is urethral hypermobility and the second is due to an inherent sphincter deficiency. In the case of urethra hypermobility, increased abdominal pressure changes the position of the urethra. On the other hand, in the inherent sphincter of the deficiency, the sphincter has lost its ability to seal the deficiency of the intestinal sphincter. The major factors propelling the growth of the female urinary incontinence treatment device market are the rising prevalence of urinary incontinence in pregnant women, stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women and rising cases of hysterectomy. Moreover, the rising incidence of obesity in the female population is the major factor expected to deliver significant growth to the market in the upcoming period.

Market Dynamics: Rising prevalence of urinary incontinence in pregnant women

According to the research published by BMC in January 2022, 1243 women were enrolled in the study. The prevalence of urinary incontinence during pregnancy was 52.0%. Most women suffer from mild or moderate incontinence. Multiple logistic regressions identified five risk factors. Urinary incontinence before pregnancy was the strongest predictor of incontinence, followed by the history of vaginal birth, coffee consumption, childhood enuresis and history of urinary tract infection. Urinary incontinence had a significant impact on health-related quality of life during pregnancy. Only 14.8% of pregnant women sought professional help for urinary symptoms. Factors significantly associated with urinary incontinence included age group, gestational age, parity, prior urinary incontinence, constipation, last childbirth mode of delivery, previous urinary tract infection, and body mass index during pregnancy.

Moreover, an increase in the penetration of private-label brands at much lower prices drives market growth in the forecast period. Due to the presence of a wide range of products on the market for female stress urinary incontinence treatment devices, small players are gaining interest and selling their products at lower prices. An increase in the penetration of private-label brands at much lower prices is expected to reduce the average overall price of female urinary incontinence stress treatment devices. It is likely to constrain the growth of the global market for female stress urinary incontinence treatment devices, as it is likely to hinder demand for expensive products.

Market Segmentation: The internal vaginal device segment is projected to be the dominant segment in the market during the forecast period.

Based on the product type, the female urinary incontinence treatment device market has been classified into urethral devices and internal vaginal devices.

The internal vaginal devices segment can be further categorized into traditional devices and custom-made devices. Urinary stress incontinence is significantly more common in women than in men. Female urinary incontinence treatment device occurs when pelvic floor muscles or urinary sphincter are likely to lose strength, either due to women's childbirth or men's prostate surgery. Thus, due to such factors, the internal vaginal device is expected to hold a dominant position in the market.

The female urinary incontinence treatment device is segmented based on end-user, which includes hospitals, speciality clinics, and ambulatory surgical centers.

The hospital pharmacies segment is expected to hold a significant market share in the female urinary incontinence treatment device market. Hospital in the end-user segment is expected to have a significant share of the global market for urinary incontinence devices due to the large patient population treated in hospitals suffering from urinary incontinence. Moreover, hospitals are expected to grow with the highest CAGR in the forthcoming period with the rise in technological advancement in the industry.

Furthermore, the female urinary incontinence treatment device is segmented on the basis of material used, which includes polyurethane foam and silicone. Polyurethane foam is the dominating segment along with projected to grow with the highest CAGR in the forthcoming period.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the female urinary incontinence treatment device market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is holding a dominant position in the global female urinary incontinence treatment device market in 2021. In North America, the U.S. is expected to represent considerable growth during the forecast period. In the U.S., the female urinary incontinence treatment device is expected to have potential growth due to the rising prevalence of urinary incontinence in pregnant women and stress urinary incontinence due to diabetes, gynecology disorders, and urinary incontinence in postmenopausal women.

The Asia-Pacific market is projected to expand significantly during the forecast period due to increased awareness, increased investment in health care to provide optimum facilities at affordable cost, and socio-economic development. The increase in the number of women smoking in China is expected to boost the market. Increased investment by prominent players in developing countries is expected to boost the market. The Middle East & Africa market is projected to expand slowly due to a lack of awareness, low disposable income, and limited healthcare facilities.

Competitive Landscape:

The key female urinary incontinence treatment device market players contributing to the global market's growth include Karl Storz, Johnson & Johnson, Coloplast, Boston Scientific, Teleflex, and American Medical Solutions, among others. The major players are adopting new product launches and expansion strategies for global growth in the female urinary incontinence treatment device market. In May 2022, Renovia, a women-led company, advances the development of digital therapeutics for female pelvic floor disorders access to first-line treatment for female urinary incontinence with 1,000 leva prescribers. Leva is a pelvic health system that is easy to use and that help woman decreases the symptoms of urinary incontinence (UI) symptoms, including overactive bladder. Leva's accelerated adoption among healthcare providers reflects their desire to improve access to conservative treatment for UI. This condition affects 62% of adult women in the U.S. and tends to progress and worsen over time. In December 2021, Caldera Medical announced FDA approval for the New Desara TVez for Stress Urinary Incontinence. The company expands its product portfolio of treatment options for women suffering from Stress Urinary Incontinence. Caldera Medical collaborated with dozens of leading surgeons to bring enhanced ease of use and patient safety to life in the form of Desara TVez. In February 2022, Cook's medical business was acquired by CooperCompanies to sell the entirety of Cook's Reproductive Health business within the MedSurg division. Cooper Companies focuses on women's health and fertility solutions, providing innovative products and services for every step in the ART journey. Some key players follow merger and collaboration strategies to expand their business. For instance, in October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals, Inc. for approximately $6.5 billion. Momenta has made excellent progress in developing its medicines for rare diseases. Together they expand their business.

COVID-19 Impact: Negative impact on the global female urinary incontinence treatment device market.

The outbreak of COVID-19 has negatively impacted the growth of the female urinary incontinence treatment device market globally. Restrictions on hospital services have affected the specialized investigation and surgical management of patients with urinary incontinence. Therefore, the COVID-19 pandemic had a negative impact on the market value of the female urinary incontinence treatment device market in 2020.

The global female urinary incontinence treatment device market report would provide an access to approximately 61 market data tables, 50 figures and 170 pages